… in Q1 2022 Sepofarsen is a potential first-in-class RNAtherapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … s epofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …